#### **Corporations: A Lever for Research and Development**

**Thomas Rockwell Mackie** 

**Emeritus Professor University of Wisconsin** 

**Director of Medical Engineering** Morgridge Institute for Research

#### **Disclosure: My Relationship with Medical Device Companies**

- Geometrics<sup>@\*</sup>
- Gammex-RMI\* Biolonix\*\$
- Adac

//// MORGRIDGE

- Shine Medical Technologies\*\$
- GE Medical
- TomoTherapy<sup>@\*</sup>
- HealthMyne<sup>@\*\$</sup>

Novelos\*\$

- Accuray<sup>\$</sup>
- CPAC@\*\$
- Accelerated Devices@\*\$
- \* Indicates Former or Current Board Membership
- @ Indicates Founder\$ Indicates Current Relationship

#### The Mine and the Mill

Good ideas tend to come from academia and get implemented and refined in a company.





The University is the Mine

The Company is the Mill

A mill won't last long if the mine is not productive.

#### Resistance to University-Industrial Partnerships

- In 1996, Lee found that only 44% of faculty agreed with policy of offering technology assistance to companies.
- And only 26% of faculty thought it was OK for the university to take equity in university startup companies.
- Faculty with the least linkage to industry had the least favorable view of university-industrial partnerships.

Lee, Y (1996) Technology transfer and the research university. A search for the boundaries of university-industry collaboration. *Research Policy* 25:843-63



# Sources of

### **Funding for R&D**

- Total US R&D spending has constant at about 2.5% of GDP.
- US federal proportion of R&D spending fell from 1965 to 2000.
- 80%+ of R&D in our field is corporate.





Divergent and Convergent Thinking: Focus is a Dimension, Not a Point















#### Why in the World Would You Want To Do This?



- What is your motivation?
- How will you get the financing needed?
- Who owns the intellectual property?
- Do you have the time?
- Will you enjoy doing it?
- Do you have business experience?
- Isn't there an easier way to accomplish your research ends?



\_



## **History of Geometrics**

- 1988 First Development to Enable Stereotactic Radiosurgery (UW First in Midwest).
- 1991 Tried to Give Away Software to Six Radiotherapy Clinics – FDA Stopped Us.
- 1992 Founding of Geometrics Corporation.
- 1996 FDA Clearance to Market.
- 1996 Sale of Geometrics to ADAC.
- 1999 Largest Selling Radiotherapy Treatment Planning Software in the World.
- 2001 Sale of ADAC to Philips Medical.
- 2014 Development team still based in Madison.



#### In 1992, Starting a UW Spin-Off Was Like Pulling Teeth



# **Founding of Geometrics**

- UW University Hospital funded development.
- FDA prohibition on clinical use of non-cleared medical software.
- Programmer funding was cut by UW Hospital.
- UW does not take an "work-for-hire" position.
- Equity in proportion to effort on development.
- Mark Gehring and Cameron Sanders went fulltime to the company.
- I and Paul Reckwerdt stayed at the UW.
- Pledged \$300,000 to UW, what it cost them.
- Gave an indefinite license to UW on derivative software that was named Pinnacle.
- License has saved UW >\$1 million in costs.



#### **Corporate Partnership**

- · Corporation gets exclusive access to IP or products in return for working capital.
- They may want an ownership interest in your company.
- · They may directly or indirectly exercise great control over your company.
- · Partnerships can maximize your exposure to the marketplace.
- · Partnerships limit the ultimate value of your company.
- · Geometrics was based on a partnership with ADAC.



#### Successful Product, **Unsuccessful Business**

- · Geometrics was funded on an advance of royalties (like a textbook).
- In 1996, ADAC received FDA 510(k) and could market Pinnacle.
- · ADAC controlled the marketing and we perceived a go-slow.
- · With what we were going to get back in royalties we would struggle to put the improvements we wanted to put into the product.
- We sold to ADAC for ~1% of eventual sales.

## **History of Tomotherapy**

1988 - First ideas at the University of Wisconsin.

. 1992 – First patents filed

Decade

- 1993 First paper of tomotherapy published.
- 1994 GE funds UW research project.
- 1996 Sale of Geometrics to ADAC.
- 1997 GE gets out of radiotherapy.
- 1997 TomoTherapy founded.
- · 1999 Received first investment.
- Two • 2002 - Received FDA 510(k) to market.
  - 2002 First patient treated at UW.
  - 2004 TomoTherapy profitable.
  - 2007 TomoTherapy goes public
  - 2011 TomoTherapy sold to Accuray

# Founding of TomoTherapy

- TomoTherapy was formed when GE got out of radiotherapy.
- We gave more than 1/3 of stock to the staff in my UW research group who joined the company.
- WARF tomotherapy patents were licensed.
- WARF was the first investor in company.
- WARF helped find VC investors.
- Low interest loan from the State of Wisconsin.
- SBIR grant from Federal government.
- First money raised was used to finish the version of the UW prototype with GE components.
- \$250,000 gift to Wisconsin Foundation.
- First sales to Canadian radiotherapy clinics.



#### Approximate Startup Budget for TomoTherapy Inc. (1998-1999)

| Legal              | 10,000    |                  |
|--------------------|-----------|------------------|
| Salary             | 40,000    |                  |
| Consulting         | 20,000    |                  |
| Accounting         | 5,000     |                  |
| Computers          | 3,000     |                  |
| Office Supplies    | 2,000     |                  |
| Travel             | 10,000    |                  |
| Rent               | 0         |                  |
| Miscellaneous      | 10,000    |                  |
| A Contractor State |           |                  |
| Total              | \$100,000 |                  |
|                    | We we     | re off by \$50.0 |



### Risk-Reward Matrix for New University Technology

|             | Low Risk   | High Risk         |
|-------------|--|-------------------|
| High Reward | Best Position,<br>But Easy to<br>License to<br>A Big Company | Most<br>Spin-Offs |
| Low Reward  |  |                   |



| Where Existing Companies<br>Perceived TomoTherapy |   |                                     |  |
|---|---|-------------------------------------|--|
|   | Low Risk                                    | High Risk                           |  |
| High Reward                                       | Best<br>Position                            | TomoTherapy                         |  |
| Low Reward  | OK, But Don't<br>Look for VC's<br>to Invest | Modern Role<br>of Big<br>Government |  |

## Where TomoTherapy Founders **Perceived Their Technology**

|             | Low Risk                                    | High Risk                           |
|-------------|---|-------------------------------------|
| High Reward |   | TomoTherapy                         |
| Low Reward  | OK, But Don't<br>Look for VC's<br>to Invest | Modern Role<br>of Big<br>Government |



#### **VC** Financing

- Necessary evil VC may be the only viable source when funding requirements are large.
  VC come in flocks and they will help you find other
- investors.
- The will be able to contribute to future rounds of financing or provide bridge loans.
- They can help you tune your business plan.
- They will be able to help with key business decisions like a merger/acquisition or a marketing decision.
- They will be able to be a bridge with investment bankers.
- Usually their interests are aligned with your's.
- TomoTherapy was VC financed (\$32 M until profitable).

#### **Issues of Conflict of Interest**

- My relationship between with the University is carefully managed by the UW Conflict of Interest committee.
- What is good for my company is not necessarily good for the UW and visa versa.
- Disclosure of the financial situation is the first requirement.
  - Disclosure to the UW
  - Disclosure in oral and written communications

## **Financial Disclosure**

"I am a co-founder of TomoTherapy Inc. (Madison, WI) which is participating in the commercial development of helical tomotherapy."



#### Do's

- Disclosure
- Disclosure
- Disclosure
- · Get everything in writing.
- I have a letter from the WI Attorney General giving official approval of my activity.
- The Smell Test Does it somehow stink (Entre Manure)?
- The Newspaper Test Imagine what a negative newspaper article would do.



#### **Absolute D'Oh's**

- Be responsible for a clinical trial involving your company's products.
- Be responsible for either end of a contract (written or verbal).
- Force your institution's co-workers or students to be involved with the company.
- Limit the rights of your institution's coworkers or students, e.g., restrict publications.



### **Conflict of Commitment**

- · When and what hats do you wear?
- You need a formal agreement with your employer on your time commitment to the company Don't assume "a day a week".
- You must not do business at your employer's place of business without compensation.
- When in doubt, your first obligation is to your employer.
- With financing of TomoTherapy I first went from a 100% appointment to a 75% appointment at the UW and finally to a 50% appointment upon IPO.

## Is There a Coincidence of Interest?

- What is good for the company may also be good for your employer.
- Is the intellectual property owned by your employer and licensed to your company?
- Does a royalty or other benefit return to your employer?
- Is there a grant or a contract linking the employer and company?
- You are not the arbitrator of what is good for your employer, only your employer is.

### Conflict/Coincidence of Interest Matrix





### Shine Medical: A Public – Private Partnership

- In 2009 Canadian NRU Reactor shut down for 15 months.
- In 2010 DOE offers cooperative agreements worth \$25 M for ideas to create a sustainable US supply of medical isotopes.
- In 2011 Morgridge Institute and Phoenix Nuclear Labs partner and obtain funding and Shine Medical is formed.
- Involves UW, multiple government labs, and private entities.
- In 2013 Environmental and Construction permits were filed with the NRC.
- In 2013 Morgridge role on the project ended.



## **Inherently Safer Than a Reactor**



## **Angel Investors**

- Behave like venture capitalists in most ways.
- Often have motivation to help their community.
- Have less capacity than venture capitalists.
- Best for early stage investments.
- Shine Medical received > \$11 M from angel investors.
- Shine needs to find >\$100 M in equity and debt financing over the next three years.











# How the Field Can Help

- Promote entrepreneurship in your university.
- Teach trainees the basics needed for business:
  - Cultural differences between academia and business,
  - Understanding finance and marketing,
  - Defining user requirements,
  - Product development and regulatory affairs,
  - Scheduling using tools like Gantt charts,
  - Useful for the working in the clinic as well.
- AAPM and other organizations in our field should partner more effectively with companies.



### Conclusions

- Corporations fund 80%+ of medical physics R&D.
- Working with companies or starting a business is an efficient way to have ideas actualized.
- You should be aware of the cultural differences between universities and companies.
- You should understand your motivation before starting a company.
- There are several ways to fund the startup of a company.
- Potential conflict of interests can be managed.
- Private-public partnerships are more likely if academics have business knowledge.

